Semaglutide

A GLP-1 receptor agonist medication used for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy).

Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk and approved by the FDA in 2017 (Ozempic, for type 2 diabetes) and 2021 (Wegovy, for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity). In the STEP-1 trial (Wilding et al., NEJM 2021), adults taking semaglutide 2.4 mg weekly lost an average of 14.9% of their body weight at 68 weeks. Semaglutide is administered as a once-weekly subcutaneous injection (Ozempic/Wegovy) or a once-daily oral tablet (Rybelsus). It works by mimicking the natural GLP-1 hormone — slowing gastric emptying, reducing appetite, and improving insulin response. Compounded semaglutide (prepared by state-licensed compounding pharmacies) is a different product from FDA-approved branded semaglutide and has not been evaluated by the FDA for safety, efficacy, or quality. Compounded formulations, strengths, and inactive ingredients may differ from the branded versions.

Ready to see if GLP-1 therapy is right for you?

Take our free 2-minute eligibility quiz. Service availability is confirmed during eligibility review.

Start Eligibility Quiz →

This glossary is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your individual health.